How We Work

Beijing Tiantan Biological Products

Back

Print

CHALLENGE

While the incidence of polio has decreased 99 percent since 1988, polio continues to exist and threatens to re-infect areas that are currently polio free. We aim to maintain immunity levels to eventually eradicate the disease by providing significant and reliable volumes of high-quality, low cost polio vaccines.

PROGRAM STRATEGY

The eradication of polio is the foundation’s number one priority. Eradication campaigns require over 2 billion doses of oral polio vaccine (OPV) per year. Reducing the cost of OPV for developing countries is necessary.

PARTNER

Beijing Tiantan Biological Products Co., Ltd.
Publicly traded, Chinese-state-controlled biopharmaceutical company engaged in research, production and distribution of vaccines, blood products and diagnostics

Foundation focus: Increase the supply of affordable OPV to support the Global Polio Eradication Initiative

INVESTMENT

Senior Unsecured Loan
Date: November 2011
Co-investors: None
Associated funding: Grant

Visit Our Blog

Connect